A team of researchers have developed genetically-engineered mice to test drugs and medical therapies. In particular, a drug is already under study with Alzheimer’s patients that blocks the production of alpha-synuclein, a central player in the disease. A mice is tested and found that can express a rare form of the human alpha-synuclein gene associated with Parkinson’s disease. The mice are already showing early signs of the disease, as well as the tell-tale presence of excess alpha-synuclein, a protein that collects in the nerve cells of people with Parkinson’s. However, it said that laboring in his lab and navigating the world of pharmaceutical product development are as different as two languages. The world of drug development is an area is still awkwardly getting to know.